U.S. markets open in 7 hours 43 minutes
  • S&P Futures

    3,930.00
    +7.50 (+0.19%)
     
  • Dow Futures

    31,998.00
    +82.00 (+0.26%)
     
  • Nasdaq Futures

    13,332.25
    +30.25 (+0.23%)
     
  • Russell 2000 Futures

    2,298.60
    +13.50 (+0.59%)
     
  • Crude Oil

    63.39
    +0.17 (+0.27%)
     
  • Gold

    1,793.20
    -4.70 (-0.26%)
     
  • Silver

    27.94
    +0.08 (+0.29%)
     
  • EUR/USD

    1.2183
    +0.0015 (+0.12%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4157
    +0.0016 (+0.11%)
     
  • USD/JPY

    105.9430
    +0.0610 (+0.06%)
     
  • BTC-USD

    50,480.88
    +36.43 (+0.07%)
     
  • CMC Crypto 200

    1,007.14
    +12.48 (+1.25%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BIIB, OTGLY and QS

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / January 7, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Biogen Inc. (NASDAQ:BIIB)
Class Period: October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline: January 12, 2021

Biogen Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in BIIB: http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=12000&from=1

CD Projekt S.A. (OTCPINK:OTGLY)
Class Period: January 16, 2020 - December 17, 2020
Lead Plaintiff Deadline: February 22, 2021

The OTGLY lawsuit alleges CD Projekt S.A. made materially false and/or misleading statements and/or failed to disclose during the class period that: Throughout the class period, defendants were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company's business, operations and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Cyberpunk 2077 was virtually unplayable on the current-generation Xbox or Playstation systems due to an enormous number of bugs; (2) as a result, Sony would remove Cyberpunk 2077 from the Playstation Store, and Sony, Microsoft and the Company would be forced to offer full refunds for the game; (3) consequently, the Company would suffer reputational and pecuniary harm; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in OTGLY: http://www.kleinstocklaw.com/pslra-1/cd-projekt-s-a-loss-submission-form?id=12000&from=1

QuantumScape Corporation f/k/a Kensington Capital Acquisition Corp. (NYSE:QS)
Class Period: December 8, 2020 - December 31, 2020
Lead Plaintiff Deadline: March 8, 2021

The QS lawsuit alleges that QuantumScape Corporation f/k/a Kensington Capital Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company's purported success related to its solid-state battery power, battery life, and energy density were significantly overstated; (2) that the Company is unlikely to be able to scale its technology to the multi-layer cell necessary to power electric vehicles; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in QS: http://www.kleinstocklaw.com/pslra-1/quantumscape-corporation-f-k-a-kensington-capital-acquisition-corp-loss-submission-form?id=12000&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/623494/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-BIIB-OTGLY-and-QS